James R. Berenson, MD

James R. Berenson, MD, is the founder, president, and chief executive officer of the Institute for Myeloma & Bone Cancer Research; president of Oncotherapeutics, a contract research organization specializing in oncology; president of James R. Berenson, MD, a clinical practice specializing in caring for patients with plasma cell dyscrasias; and founder and chief scientific officer of OncoTracker, a biotech company with a focus on cancer diagnostics and therapeutics.

After receiving a bachelor of science degree with distinction from Stanford University, he earned his doctorate in Medicine from the University of California at San Diego. Dr Berenson completed his internship and residency in Internal Medicine at the University of Utah Medical Center and fellowships in Hematology/Oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.

Dr Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as chief of medical oncology and cancer research as well as director of research at the Greater Los Angeles Veterans Administration Healthcare Systems. He has specialized in research related to myeloma and metastatic bone disease in both the basic and clinical areas for more than 35 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases, resulting in improvements in the length and quality of their lives. He also consults and receives research funding and honorarium from Celgene, Takeda, Amgen, Janssen, and Bristol Myers Squibb. He has also received research funding and consulting from Incyte.

He has authored and coauthored numerous books, articles, and abstracts in critically renowned journals. Dr Berenson serves as a member of the National Institutes of Health Center for Scientific Review, Clinical Oncology Study Section, and is a member of the scientific boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He also serves on the foundation and the scientific boards of the Leukemia & Lymphoma Society and the Scientific Board of the International Waldenstrom’s Macroglobulinemia Foundation.